rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The OPRM1 (rs1799971) polymorphism was investigated in an association study of a group of ADS patients (n = 177) and in subgroups (delirium tremens and/or seizures, age at onset <26 years, dissocial alcoholics, positive familial history of alcoholism, delirium tremens, and seizures).
|
30085428 |
2019 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Individuals (n = 146) meeting DSM-IV criteria for alcohol dependence who were genotyped for the OPRM1 A118G SNP and who did, or did not, use nicotine/cigarettes were randomized, in a balanced fashion, to naltrexone (50 mg/d) or placebo and provided medical management (MM) over a 16-week clinical trial.
|
29431852 |
2018 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
OPRM1 A118G and serum β-endorphin interact with sex and digit ratio (2D:4D) to influence risk and course of alcohol dependence.
|
30322771 |
2018 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Lack of associations of the opioid receptor mu 1 (OPRM1) A118G polymorphism (rs1799971) with alcohol dependence: review and meta-analysis of retrospective controlled studies.
|
29070014 |
2017 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It is premature to use the Asn40Asp polymorphism as a biomarker to predict the response to naltrexone treatment of alcohol dependence.
|
25760804 |
2015 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genetic analyses of the level of response to alcohol, particularly of the functional OPRM1 A118G polymorphism and 5' and 3' functional polymorphisms in SLC6A4, are beginning to provide insights into the etiology of alcoholism and also genotype-stratified subgroup responses to naltrexone and SSRIs/ondansetron respectively.
|
24220019 |
2014 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A single-nucleotide polymorphism (SNP) within the OPRM1 gene, A118G, leading to an amino acid change (Asn40Asp) in the extracellular portion of the receptor, has been implicated in alcoholism as well as in drug addiction, pain sensitivity and stress response, and in animal and human studies relates to the alcohol-dependent phenotype as well as to the treatment response to the µ-opioid antagonist naltrexone.
|
23543091 |
2014 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The association between the OPRM1 A118G (Asn40Asp, rs1799971) polymorphism and alcohol use disorders and alcohol consumption was analyzed using three different population-based samples: (a) a Finnish cohort study, Health 2000, with 503 participants having a DSM-IV diagnosis for alcohol dependence and/or alcohol abuse and 506 age- and sex-matched controls; (b) a Finnish cohort study, FINRISK (n = 2360) and (c) the Helsinki Birth Cohort Study (n = 1384).
|
23729673 |
2014 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The A118G (rs 1799971) polymorphism in the mu-opioid receptor gene (OPRM1) has been reported to be associated with alcohol addiction.
|
23254216 |
2013 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Variation at a single nucleotide polymorphism in the μ-opioid receptor gene (OPRM1), A118G (Asn40Asp), may moderate naltrexone (NTX) effects in alcohol dependence.
|
23032071 |
2013 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The Asn40Asp variant (A118G) of the μ opioid receptor (OPRM1) gene is thought to contribute to the development and treatment of alcohol dependence.
|
22397905 |
2013 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The best-studied functional genetic variant relevant to alcoholism treatment is rs1799971, a single-nucleotide polymorphism in exon 1 of the OPRM1 gene that encodes the μ-opioid receptor.
|
22587755 |
2012 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The OPRM1 A118G polymorphism may contribute to the susceptibility of alcohol dependence in Asians but not in Caucasians.
|
22071118 |
2012 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although screening of patients in a clinical setting remains premature, results suggest the A118G substitution may influence one etiological pathway to alcoholism, for which naltrexone pharmacotherapy is more effective.
|
22909206 |
2012 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Six previous studies have analyzed the role of A118G</span> polymorphism in response to naltrexone for alcohol dependence.
|
22515274 |
2012 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Conflicting results were reported on the role of the mu-opioid receptor (OPRM1) polymorphism A118G (Asn40Asp, rs1799971) in the development of alcoholism.
|
22309038 |
2012 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Recent clinical and laboratory studies have shown that the effects of naltrexone for alcoholism may be moderated by the Asn40Asp single-nucleotide polymorphism (SNP) of the μ-opioid receptor gene (OPRM1).
|
21900886 |
2012 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This paper will review converging lines of evidence on the effect of the Asn40Asp SNP on alcoholism phenotypes, including: (i) genetic association studies; (ii) behavioral studies of alcoholism; (iii) neuroimaging studies; (iv) pharmacogenetic studies and clinical trials; and (v) preclinical animal studies.
|
21895723 |
2012 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Two hundred and sixty-five nontreatment-seeking individuals with alcohol dependence were genotyped a priori for the OPRM1 asn40asp SNP and post hoc for DAT (SLC6A3) 9 and 10 VNTRs.
|
22551036 |
2012 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.
|
21946895 |
2011 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Results suggest that the association of A118G polymorphism to heroin and alcohol addiction may be because of the altered regulation of PKA and pERK1/2 during opioid and alcohol exposures.
|
19891732 |
2010 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results suggest main effect of education background, OPRM1 A118G, and DRD2 -141C Ins/Del as well as education*OPRM1 interaction in contribution to moderate and/or severe alcoholism in Mexican Americans.
|
19764934 |
2009 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These results do not support association of the OPRM1 Asn40Asp polymorphism with NTX treatment response for AD.
|
17374034 |
2007 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the present study, we compared the frequencies of the polymorphism OPRM1 A118G between patients with alcohol dependence and healthy control subjects living in a Japanese provincial prefecture.
|
16679777 |
2006 |
rs1799971
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Functional alleles that alter alcoholism-related intermediate phenotypes include common alcohol dehydrogenase 1B and aldehyde dehydrogenase 2 variants that cause the aversive flushing reaction; catechol-O-methyltransferase (COMT) Val158Met leading to differences in three aspects of neurobiology: executive cognitive function, stress/anxiety response, and opioid function; opioid receptor micro1 (OPRM1) Asn40Asp, which may serve as a gatekeeper molecule in the action of naltrexone, a drug used in alcoholism treatment; and HTTLPR, which alters serotonin transporter function and appears to affect stress response and anxiety/dysphoria, which are factors relevant to initial vulnerability, the process of addiction, and relapse.
|
15584875 |
2004 |